Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: RNA sequencing of MC38 mouse tumor tissue with and without drug over time

PROVIDER: PRJNA477557 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7414690_1.fastq.gz	Fastqsanger.gz
	SRR7414690_2.fastq.gz	Fastqsanger.gz
	SRR7414700_1.fastq.gz	Fastqsanger.gz
	SRR7414700_2.fastq.gz	Fastqsanger.gz
	SRR7414710_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 171

Similar Datasets

Project description:RNA sequencing of B16F0 syngeneic mouse tumor tissue with and without drug over time

| PRJNA478383 | ENA

Project description:RNA sequencing of EMT6 syngeneic mouse tumor tissue with and without drug over time

| PRJNA478198 | ENA

Project description:RNA sequencing of MC38 mouse tumor tissue with escalating drug dose

| PRJNA477829 | ENA

Project description:RNA sequencing of MC38 mouse tumor tissue treated +/- drug and +/- immune cell depletion

| PRJNA477845 | ENA

RNA-sequencing on sorted infiltrating CD8 T cells from vehicle or JHU083, pro-drug of 6-Diazo-5-oxo-L-norleucine (glutamine antagonist) treated MC38 (colon cancer) tumor bearing mice

Project description:RNA-sequencing was performed on sorted CD11b-CD11c-B220-CD45+TCRbeta+CD44+CD8+ TIL from vehicle or JHU083 treated MC38 tumor-bearing mice with or without JHU083, pro-drug of 6-Diazo-5-oxo-L-norleucine (glutamine antagonist) treatment for expression profiling

2020-02-24 | GSE120345 | GEO

Transcriptional response to vanoxerine in vivo treatments in MC38 colorectal tumors

Project description:Murine colorectal cancer MC38 cells were injected in the flank of C57BL/6 mice to form tumor grafts over 7 days. Tumor-bearing mice were treated with daily injections of vanoxerine (25mg/kg) or vehichle control (saline) over 10 consecutive days. Tumors were excised and RNA sequencing profiling was performed on both experimental condition.

2022-07-13 | GSE207032 | GEO

Single cell TCR-seq profiling of T cells isolated from LNs of MC38 tumor-bearing mice

Project description:We investigate the single-cell landscape of the inflammatory mouse tumor model MC38, a C57BL/6 tumor cell line derived from colon adenocarcinoma. MC38 (diluted in HBSS and matrigel) was inoculated in the right unilateral flank (in the border of positions B2 and B3) of C57BL/6 mice (ref Study 16-3384 AV). Draining lymph nodes were taken one day after group-out (average 150-250 mm3 tumor size at day 0), approximately 14-19 days. Draining lymph nodes were dissociated and flow sorted accordingly to obtain the cells for 10x Chromium 5' Gene Expression Profiling and TCR sequencing.

2022-08-16 | E-MTAB-9734 | biostudies-arrayexpress

Project description:MC38 Mouse Tumor Model Characterization

| PRJNA551473 | ENA

The diapause-like colorectal cancer cells induced by SMC4 attenuation are characterized by low proliferation and chemotherapy insensitivity[scRNA-seq]

Project description:We used single-cell sequencing to detect tumor cell types in mouse subcutaneous MC38 colorectal cancer

2023-06-20 | GSE234240 | GEO

Next generation sequencing of a unique set of glycovariant MC38 mouse colorectal cancer cell lines generated with CRISPR-Cas9 and CRISPR-dCas-VPR technology

Project description:To investigate the effect of different tumor-associated glycans, mouse colorectal cancer cells (MC38 cell line) were genetically modified using CRISPR-Cas9 and CRISPR-dCas-VPR technology targeting different genes involved in glycosylation pathways. To study the effect of altered glycosylation at the transcriptional level, next generation sequencing was performed on the entire panel of glycovariant MC38 cell lines. The MC38 knockout cell lines created with the CRISPR-Cas9 technology are: MC38-MOCK#1, MC38-CMAS KO, MC38-COSMC KO, MC38-CMAS+COSMC KO. The MC38 overexpressing cell lines generated with the CRISPR-dCas9-VPR technology are: MC38-MOCK#2, MC38-FUT4, MC38-FUT9. Details on the cell lines can be found in the corresponding manuscript(s).

2020-08-05 | GSE143700 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data